D. O. Clegg, D. J. Reda, M. H. Weisman, J. J. Cush, F. B. Vasey, H. R. Schumacher Jr., E. Budiman-Mak, D. J. Balestra, W. D. Blackburn, G. W. Cannon, R. D. Inman, F. P. Alepa, E. Mejias, M. R. Cohen, R. Makkena, M. L. Mahowald, J. Higashida, S. L. Silverman, N. Parhami, J. Buxbaum, C. M. Haakenson, R. H. Ward, B. J. Manaster, R. J. Anderson, W. G. Henderson, et al., “Comparison of Sulfasalazine and Placebo in the Treatment of Reactive Arthritis (Reiter’s Syndrome). A Department of Veterans Affairs Cooperative Study,” Arthritis & Rheumatism, Vol. 39, No. 12, 1996, pp. 2021-2027.
http://dx.doi.org/10.1002/art.1780391211

has been cited by the following article:

• TITLE: Reactive Arthritis: From Clinical Features to Pathogenesis

  AUTHORS: Ethelina Cargnelutti, María Silvia Di Genaro

  KEYWORDS: Reactive Arthritis; HLA-B27; Spondyloarthritis; Yersinia-Induced ReA; Therapy

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.4 No.12B, December 27, 2013

  ABSTRACT: Reactive arthritis (ReA) is a sterile synovitis which occurs after a gastrointestinal or urogenital infection. ReA belongs to Spondyloarthritis (SpA), a group of diseases that share several clinical and radiological features including familiar clustering, absence of rheumatoid factor and association with HLA-B27. Clinically, ReA is characterized by an asymmetric arthritis predominantly affecting the lower limbs, often associated with urethritis, conjunctivitis and other extraarticular symptoms. The ReA prevalence depends on the incidence of causative pathogens. The ReA diagnosis is based on clinical features and serological tests to evidence previous infection. Different treatment including antibiotics, disease modifying antirheumatic drugs (DMARs) and biologic agents has been recommended. Even though knowing that infections trigger the joint inflammation, the ReA pathogenesis remains to be poorly understood. Several animal models and in vitro studies have been used to elucidate the mechanisms involved in ReA development. In this sense, HLA-B27 transgenic rat or mice have been used to explain the role of this molecule in SpA aetiopathogenesis. Moreover, the infectious model of Yersinia-induced ReA in rodents has shed some lights on the relationship between host genetic susceptibility to infection and abnormal immune response in ReA development. Understanding the immune mediators triggering ReA will contribute to find a specific treatment for this arthritis. In this review, we focus on clinical features, epidemiology, treatment, and the different attempts to understand the pathogenesis of ReA.